Ligand Pharmaceuticals (LGND) Profit After Tax (2010 - 2026)

Ligand Pharmaceuticals (LGND) has 17 years of Profit After Tax data on file, last reported at -$13.3 million in Q1 2026.

• For the quarter ending Q1 2026, Profit After Tax rose 68.56% year-over-year to -$13.3 million; the trailing twelve-month figure through Mar 2026 stood at $153.6 million (up 215.79% YoY), and the FY2025 full-year result was $124.5 million, up 3186.63% from the prior year.
• Profit After Tax fell to -$13.3 million in Q1 2026, from $44.8 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $117.3 million in Q3 2025 to a low of -$51.9 million in Q2 2024.
• A 5-year average of $7.4 million and a median of -$895000.0 in 2022 frame the typical range for Profit After Tax.
• Across the five-year window, Profit After Tax sank 2642.82% in 2023 and jumped 1735.15% in 2025, its largest moves.
• Tracing LGND's Profit After Tax over 5 years: stood at -$17.5 million in 2022, then soared by 204.02% to $18.2 million in 2023, then sank by 270.93% to -$31.1 million in 2024, then surged by 244.06% to $44.8 million in 2025, then plunged by 129.8% to -$13.3 million in 2026.
• Business Quant data shows LGND's Profit After Tax at -$13.3 million in Q1 2026, $44.8 million in Q4 2025, and $117.3 million in Q3 2025.